Open-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 10, 1998, Pages 737-745

  Castaño, Gladys ^a   Más, Rosa ^a   Fernández, Julio César ^a   Pontigas, Virginia ^a   Suazo, Magnolia ^a   Fernández, Lilia ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Cholesterollowering drugs; Dyslipidemia; Policosanol; Type II hypercholesterolemia

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIAPHORESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

EID: 0031787854     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85033-9     Document Type: Article

References (40)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984; 251:351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Frick MH, Elo D, Haapa K, et al. Helsinki Heart Study: Primary intervention trial with gemfibrozil in middle-aged men with dislipidemia. NEJM. 1987;317:1237-1245.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383-1389.
5. Sheperd J, Cobbe SM, Christopher G, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;333:1301-1307.
6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. O'Connor P, Feely J, Sheperd J. Lipid lowering drugs. BMJ. 1990;300:667-672.
8. Steiner A, Weisser B, Vetter W. A comparative study of the adverse effects of treatment for hyperlipidemia. Drug Safety. 1991;6:118-130.
9. Deslypere JP. The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: A review of fluvastatin. Curr Ther Res. 1995;56:111-128.
10. Plosker GL, McTavish D. Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs. 1995;50:334-363.
11. Aneiros E, Calderón B, Más R, et al. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res. 1993;54:304-315.
12. Soltero I, Fuenmayor I, Colmenares J. Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch Venezol Farmacol Terap. 1993;12:71-76.
13. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
14. Pons P, Rodríguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
15. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
16. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
17. Canetti M, Moreira M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res. 1995;15:159-165.
18. Castaño G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hyperlipoproteinemia: A 12-month study. Curr Ther Res. 1995;56: 819-828.
19. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
20. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
21. Castaño G, Illnait J, Fernández L, et al. Estudio dosis-efecto de la acción hipocolesterolémica del policosanol en pacientes con hiperlipoproteinemia tipo II. Rev CENIC Cien Biol. 1996;27:38-40.
22. Castaño G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res. 1996;57:691-699.
23. Castaño G, Nodarse M, Más R, et al. Comparación de los efectos del policosanol y la lovastatina en pacientes con hipercolesterolemia primaria tipo II. Rev CENIC Cien Biol. 1996;27:57-63.
24. Castaño G, Más R, Fernández JC, Illnait J. Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1997; 58:154-162.
25. Campilongo R, Sandini P, Feldman R, et al. Eficacia, seguridad y tolerabilidad del policosanol en pacientes argentinos con hipercolesterolemia tipo II. Estudio abierto. Prensa Méd Argent. 1996;83:665-672.
26. Pons P, Illnait J, Más R, et al. A comparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res. 1997;58:26-35.
27. Crespo N, Alvarez R, Más R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia. Curr Ther Res. 1997; 58:44-51.
28. Ortensi G, Gladstein H, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:390-401.
29. Alemán CL, Rodeiro I, Noa M, et al. Acute, subchronic and chronic toxicity of policosanol in rats. Presented at the Sixth International Congress of Toxicology, Rome, June 28-July 3. 1992:248. Abstract.
30. Alemán CL, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
31. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
32. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
33. Rodríguez C, Mesa R, Más R, et al. Effect of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
34. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutag. 1994;14:107-113.
35. Alemán C, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: An 18 month study. Food Chem Toxicol. 1995;33:573-578.
36. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factor limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
37. Assmann G, Schulte H. Diabetes mellitus and hypertension in the elderly: Concomitant hyperlipidemia and coronary heart disease risk. Am J Cardiol. 1989;63(Suppl H):33-37.
38. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
39. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
40. Illingworth DR. An overview of lipid-lowering. Drugs. 1988;86(Suppl 3):63-71.